Analyst Warns Eli Lilly’s GLP-1 Lead Is Fading as CFRA Lifts Rating to Buy

Overview

• TheoTrade’s Don Kaufman argued Lilly’s GLP-1 lead is narrowing as rivals develop similar drugs and patent protections prove difficult to defend.
• PGIM Jennison’s Q2 letter described Lilly as a diversified biopharma leader with tirzepatide delivering the strongest launch in diabetes and obesity under Mounjaro and Zepbound.
• The investor letter said the latest quarter showed a small tirzepatide beat, with a minor U.S. Mounjaro miss offset by strong Zepbound sales and robust international growth.
• PGIM Jennison reported no guidance increase, noted margins and EPS topped expectations, and attributed a modest full-year EPS trim to acquired in-process R&D accounting.
• CFRA upgraded Lilly to Buy with an $835 price target, citing 38% Q2 revenue growth to $15.56 billion driven by Zepbound and Mounjaro, and it referenced higher 2025 guidance.